DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.53

Change

+0.04 (+0.47)%

Market Cap

USD 0.17B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.53 (+0.53%)

USD 16.82B
IVV:AU iShares Core S&P 500 AUD

-0.03 (-0.05%)

USD 8.73B
VGS:AU Vanguard MSCI International Sh..

+0.08 (+0.06%)

USD 8.59B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.24 (+0.44%)

USD 6.70B
IOZ:AU Ishares Core S&P/Asx 200

+0.21 (+0.64%)

USD 6.18B
STW:AU SPDR® S&P/ASX 200 Fund

+0.49 (+0.67%)

USD 5.58B
NDQ:AU Betashares Nasdaq 100

+0.08 (+0.18%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.33 (+0.82%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.81 (+0.60%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

-0.38 (-0.09%)

USD 4.71B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.70% 51% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.70% 51% F 52% F
Trailing 12 Months  
Capital Gain 13.28% 42% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.28% 43% F 51% F
Trailing 5 Years  
Capital Gain 38.93% 80% B- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.93% 80% B- 58% F
Average Annual (5 Year Horizon)  
Capital Gain 7.01% 77% C+ 56% F
Dividend Return 8.57% 73% C 55% F
Total Return 1.56% 52% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 8.42% 64% D 93% A
Risk Adjusted Return 101.74% 96% N/A 98% N/A
Market Capitalization 0.17B 34% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.